Literature DB >> 11978653

Advanced glycation end product precursors impair epidermal growth factor receptor signaling.

Manuel Portero-Otín1, Reinald Pamplona, Maria Josep Bellmunt, Maria Cristina Ruiz, Joan Prat, Robert Salvayre, Anne Nègre-Salvayre.   

Abstract

Formation of advanced glycation end products (AGEs) is considered a potential link between hyperglycemia and chronic diabetic complications, including disturbances in cell signaling. It was hypothesized that AGEs alter cell signaling by interfering with growth factor receptors. Therefore, we studied the effects of two AGE precursors, glyoxal (GO) and methylglyoxal (MGO), on the epidermal growth factor receptor (EGFR) signaling pathway in cultured cells. Both compounds prevented tyrosine autophosphorylation induced by epidermal growth factor (EGF) in a time- and dose-dependent manner as well as phospholipase Cgamma1 recruitment and subsequent activation of extracellular signal-regulated kinases. AGE precursors inhibit EGF-induced EGFR autophosphorylation and tyrosine kinase activity in cell membranes and in EGFR immunoprecipitates. In addition, AGE precursors strongly inhibited cellular phosphotyrosine phosphatase activities and residual EGFR dephosphorylation. AGE precursors induced the formation of EGFR cross-links, as shown by the cross-reactivity of modified EGFR with an anti-N(epsilon)(carboxymethyl)lysine antibody, suggesting that altered EGFR signaling was related to carbonyl-amine reactions on EGFR. Aminoguanidine, an inhibitor of AGE formation, partially prevented the EGFR dysfunction induced by GO and MGO. These data introduce a novel mechanism for impaired cellular homeostasis in situations that lead to increased production of these reactive aldehydes, such as diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11978653     DOI: 10.2337/diabetes.51.5.1535

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  17 in total

1.  Proteomic analysis of proteins associated with cellular senescence by calorie restriction in mesenchymal stem cells.

Authors:  Hyun-Jung Kim; Bo-Ram Ji; Ji-Soo Kim; Han-Na Lee; Dong-Ho Ha; Chan-Wha Kim
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-03       Impact factor: 2.416

Review 2.  Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC.

Authors:  Kenichi Tamama; Haruhisa Kawasaki; Alan Wells
Journal:  J Biomed Biotechnol       Date:  2010-02-17

Review 3.  Diabetic lower extremity wounds: the rationale for growth factors-based infiltration treatment.

Authors:  Jorge Berlanga-Acosta
Journal:  Int Wound J       Date:  2011-09-13       Impact factor: 3.315

4.  Increased expression of advanced glycation end-products and their receptor, and activation of nuclear factor kappa-B in lacrimal glands of diabetic rats.

Authors:  M Alves; V C Calegari; D A Cunha; M J A Saad; L A Velloso; E M Rocha
Journal:  Diabetologia       Date:  2005-11-08       Impact factor: 10.122

5.  Cell death and learning impairment in mice caused by in vitro modified pro-NGF can be related to its increased oxidative modifications in Alzheimer disease.

Authors:  Anton Kichev; Ekaterina V Ilieva; Gerard Piñol-Ripoll; Petar Podlesniy; Isidro Ferrer; Manuel Portero-Otín; Reinald Pamplona; Carme Espinet
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

Review 6.  Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors.

Authors:  A Negre-Salvayre; C Coatrieux; C Ingueneau; R Salvayre
Journal:  Br J Pharmacol       Date:  2007-07-23       Impact factor: 8.739

Review 7.  Epidermal growth factor in clinical practice - a review of its biological actions, clinical indications and safety implications.

Authors:  Jorge Berlanga-Acosta; Jorge Gavilondo-Cowley; Pedro López-Saura; Tania González-López; María D Castro-Santana; Ernesto López-Mola; Gerardo Guillén-Nieto; Luis Herrera-Martinez
Journal:  Int Wound J       Date:  2009-10       Impact factor: 3.315

8.  Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction.

Authors:  Ariana García Ojalvo; Jorge Berlanga Acosta; Yssel Mendoza Marí; Maday Fernández Mayola; Calixto Valdés Pérez; William Savigne Gutiérrez; Ileydis Iglesias Marichal; Eduardo Álvarez Seijas; Alicia Molina Kautzman; Angélica Estrada Pacheco; David G Armstrong
Journal:  Int Wound J       Date:  2016-03-22       Impact factor: 3.315

9.  The chaperone-dependent ubiquitin ligase CHIP targets HIF-1α for degradation in the presence of methylglyoxal.

Authors:  Carla Figueira Bento; Rosa Fernandes; José Ramalho; Carla Marques; Fu Shang; Allen Taylor; Paulo Pereira
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

10.  Advanced glycation end products: Key players in skin aging?

Authors:  Paraskevi Gkogkolou; Markus Böhm
Journal:  Dermatoendocrinol       Date:  2012-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.